Eli Lilly
Lilly Expands Obesity Drug Range Amid Safety Trials
Eli Lilly is aggressively pursuing advancements in the field of obesity treatment, accelerating the development of an oral medication option ...
Eli Lilly Expands Manufacturing to Meet Mounjaro Demand Surge
Eli Lilly’s diabetes medication Mounjaro has continued to experience robust sales growth despite supply challenges, with the GLP-1/GIP agonist generating ...
Eli Lilly launches Omvoh for ulcerative colitis after FDA nod
Eli Lilly, known for its weight loss contender Mounjaro, is making strides in the immunology arena. The FDA has granted ...
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC
ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...
Eli Lilly sues fake Mounjaro sellers for trademark infringement and false advertising
Eli Lilly, the pharmaceutical giant, is intensifying its legal efforts to combat unauthorized versions of its popular diabetes drug, Mounjaro. ...
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
Lilly’s mirikizumab shows promise in Crohn’s disease after failing in psoriasis
After a previous setback when the FDA withheld approval for mirikizumab in ulcerative colitis due to manufacturing issues, Eli Lilly’s ...
FDA warns companies selling unauthorized obesity drugs similar to Wegovy and Mounjaro
The soaring demand for new anti-obesity medications has led to a concerning trend, with various online companies attempting to sell ...
Eli Lilly Reshuffles C-Suite Leadership Amid Crucial Mounjaro Decision Looming
Eli Lilly is undergoing leadership changes in its diabetes and obesity division as it anticipates a significant FDA decision in ...
Lilly Makes a Splash in Radiopharmaceuticals with $1.4B Acquisition of Point Biopharma
Eli Lilly is making a significant foray into the radiopharmaceutical cancer therapeutic sector with its acquisition of Point Biopharma Global ...
Eli Lilly Faces Third FDA Rejection in 2023, Eczema Drug Lebrikizumab Denied Approval
Eli Lilly, which had set ambitious plans to introduce four new drugs in 2023, has faced another setback on the ...
Eli Lilly settles Whistleblower lawsuit over alleged quality issues
Settlement talks have been underway between pharmaceutical giant Eli Lilly and a former human resources officer, Amrit Mula, who blew ...
Lilly secures Emgality’s future after judge invalidates Teva’s patents
A federal judge in Massachusetts has ruled in favor of Eli Lilly, overturning a $176.5 million jury verdict issued in ...
Jardiance gets FDA green light for chronic kidney disease, challenging AstraZeneca’s rival drug
Shortly after securing European approval for the treatment of chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim have achieved ...
NICE approves Lilly’s Omvoh for ulcerative colitis after FDA rejection, citing cost-effectiveness and clinical benefits
“In a significant turn of events, Eli Lilly, despite initial setbacks in the US market with its ulcerative colitis drug ...
Eli Lilly Sues 8 Companies for selling fake Mounjaro versions
The surging demand for GLP-1 diabetes and weight loss medications has led to an inevitable influx of knockoff versions. Earlier ...
Novo and Lilly’s obesity drugs face barriers of high price and low coverage, survey shows
A recent survey of 100 doctors in the United States who prescribe weight loss medications has revealed that over 75% ...
Almirall uses famous paintings to raise awareness of atopic dermatitis
Almirall, a Barcelona-based pharmaceutical company collaborated with Eli Lilly on the development of the atopic dermatitis drug candidate lebrikizumab, has ...
Novo Nordisk’s Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
Eli Lilly’s Mounjaro gets NICE approval for type 2 diabetes after cost-effectiveness review
Eli Lilly’s diabetes medication, Mounjaro (tirzepatide), has been on a winning streak since its US launch in May, and now ...
Nine States Pushback Against Lilly’s $13.5M Insulin Pricing Settlement
In a dramatic legal showdown, nine states are raising objections to a potentially game-changing $13.5 million settlement that pharmaceutical giant ...
Boehringer’s Obesity Drug with Dual Mechanism Ready for Phase III
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising ...
Novo Nordisk and Eli Lilly Ride Obesity and Diabetes Drugs to the Forefront in Q2 Pharmaceutical Performance
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, ...
How Mounjaro Boosted Eli Lilly’s Sales and Fought Obesity
As Eli Lilly’s flagship diabetes medication, Mounjaro, continues its meteoric rise in popularity and edges closer to potential approval for ...
Lilly’s Retevmo Outperforms Gavreto in Lung Cancer Study
Source – Eli Lilly In the ongoing rivalry between Eli Lilly and Blueprint Medicines over their RET inhibitors, Eli Lilly ...
A user of well-known GLP-1 medications has filed a lawsuit against Novo Nordisk and Eli Lilly
As Novo Nordisk and Eli Lilly enjoy significant sales from their GLP-1 diabetes and obesity drugs, they also face legal ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk
Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...
Jardiance Receives EU Approval for Treating Chronic Kidney Disease (CKD), Posing a Strong Challenge to Forxiga
Source – Boehringer Ingelheim The European Union has granted approval for Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), ...
